补充图3。Correlation of ctDNA VAF baseline values with A. tumor load (RECIST 1.1) in the group of IHCC patients ( P= 0.5013, r=0.1956, Spearman), B. tumor load (RECIST 1.1) in the group of EHCC patients ( P= 0.0962, r=0.5370 Spearman), C. progression- free survival (PFS) in the group of EHCC patients ( P= 0.2380,r = -0.2974,Spearman)。D. PFS患者的突变数量的相关性(P = 0.0907,R = -0.3988,Spearman)。E. kaplan-Meier在BAP1,PBRM1,KRAS或TP53患者中与没有突变的患者中突变患者的PFS图(P = 0.1200,Mantel-Cox)。IHCC-肝内胆管癌,EHCC-肝外胆管癌。IHCC-肝内胆管癌,EHCC-肝外胆管癌。